Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02822937 · ClinicalTrials.gov registry record · NA
Sensitivity of Project: EVO Monitor Cognitive Measurements to Pharmacological Agents
A NA study, sponsored by Akili Interactive Labs.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT02822937 is a NA study that has completed, run by Akili Interactive Labs. The registered enrollment target is 18 participants.
The verdict
NCT02822937, a NA study, has completed, sponsored by Akili Interactive Labs.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a study in adults to assess the sensitivity of Project: EVO Monitor cognitive measurements to two short-acting cognitively active pharmacological agents. The participants will receive a placebo, and two pharmacological agents in a randomized order for three in-clinic study days. During each study day in the clinic, the participants will use Project: EVO Monitor and another cognitive task through the day.
Interventions
- DRUG Placebo
- DRUG Methylphenidate
- DRUG Triazolam
- OTHER Project: EVO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-07 |
| Est. Completion | 2016-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02822937
The ClinicalTrials.gov registry entry for NCT02822937 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akili Interactive Labs, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02822937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02822937 about?
NCT02822937 is a clinical study titled "Sensitivity of Project: EVO Monitor Cognitive Measurements to Pharmacological Agents". This is a study in adults to assess the sensitivity of Project: EVO Monitor cognitive measurements to two short-acting cognitively active pharmacological agents. The participants will receive a placebo, and two pharmacological agents in a randomized order for three in-clinic study days. During each ...
What is the current status of trial NCT02822937?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2016-07. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02822937?
The interventions under investigation include: Placebo (DRUG), Methylphenidate (DRUG), Triazolam (DRUG), Project: EVO (OTHER).
Who is sponsoring clinical trial NCT02822937?
This trial is sponsored by Akili Interactive Labs, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.